CHDS’ Soroush Saghafian, his lab, the Public Impact Analytics Science Lab (PIAS-Lab), and the Dana Farber Cancer Institute recently received a grant from the Department of Defense (DOD) to use artificial intelligence (AI) to analyze genomic data in the identification of optimum treatment for individual melanoma patients.
Researchers have identified molecular biomarkers that predict immunotherapy resistance and toxicity in melanoma. The goal of this project is to develop biomarkers of disease progression, treatment resistance and toxicity, and to integrate these into a quantitative decision framework that can guide individualized treatment decisions. The PIAS-Lab will develop predictive and prescriptive analytic models that integrate clinical and molecular features to guide individualized treatment plans.
Saghafian explained, “these are treatments that are fully personalized to each patient using genomic data and provide the sort of solutions that the doctors might not be able to figure out or to come up with.” The project will also build a chatbot system for physicians to be able to question the AI recommendations. This system could also provide improved knowledge of medicine and healthcare operations to policymakers.
Learn more: Read the Harvard Crimson article, Harvard Kennedy School Public Impact Analytics Science Lab Receives $3 Million From DOD
Learn more: Read about the Public Impact Analytics Science Lab
Related news: ISPOR Panel on Health Economics and Generative AI
Related news: Soroush Saghafian: Making AI Impactful in Healthcare and Public Policy